机构：[1]Tulane Univ, Dept Struct & Cellular Biol, New Orleans, LA 70112 USA;[2]Tulane Univ, Dept Orthopaed Surg, New Orleans, LA 70112 USA;[3]Kunming Med Univ, Affiliated Hosp 1, Dept Gynecol, Kunming, Yunnan, Peoples R China;昆明医科大学附属第一医院[4]Shaanxi Univ Chinese Med, Affiliated Hosp 2, Dept Clin Med, Xian, Shaanxi, Peoples R China;[5]Xavier Univ Louisiana, RCMI Canc Res Ctr, Dept Comp Sci, New Orleans, LA USA;[6]Xavier Univ Louisiana, RCMI Canc Res Ctr, Biostat Facil, New Orleans, LA USA;[7]Meharry Med Coll, Sch Med, Dept Biochem & Canc Biol, Nashville, TN 37208 USA;[8]Tulane Univ, Tulane Canc Ctr, New Orleans, LA 70112 USA;[9]Tulane Univ, Louisiana Canc Res Consortium, New Orleans, LA 70112 USA;[10]Tulane Univ, Tulane Ctr Stem Cell Res & Regenerat Med, New Orleans, LA 70112 USA;[11]Tulane Univ, Tulane Ctr Aging, New Orleans, LA 70112 USA;[12]Southeast Louisiana Vet Hlth Care Syst, 2400 Canal St, New Orleans, LA 70119 USA;[13]Tulane Univ, Sch Med, Dept Struct & Cellular Biol, 1430 Tulane Ave Mailbox 8649, New Orleans, LA 70112 USA
Interleukin-17 (IL-17) has been demonstrated to promote development of a variety of cancers including prostate cancer in genetically modified mouse models. IL-17 is the main product secreted by T helper 17 (Th17) cells. A recent study has shown that Th17 cells and related genes are upregulated in human prostate cancers. However, there is no direct experimental evidence to demonstrate Th17's role in prostate cancer. In the present study, we co-implanted mouse prostate cancer MPC3-luc cells with Th17-polarized mouse splenocytes in the prostate of immunocompetent C57BL/6J male mice. We found that Th17-polarized splenocytes promoted orthotopic allograft prostate tumor growth compared to the control splenocytes. The numbers of IL-17-positive lymphocytes and macrophages were higher in the prostate tumors grown from co-implantation of MPC3-luc cells and Th17-polarized splenocytes, compared to the prostate tumors grown from co-implantation of MPC3-luc cells and control splenocytes. Our findings provide the first direct experimental evidence that Th17 cells may promote prostate cancer growth.
基金：
National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01CA174714]; Department of DefenseUnited States Department of Defense [W81XWH-15-1-0444]; Transformative Experiment Fund of Tulane Cancer Center (TCC); Louisiana Cancer Research Consortium (LCRC) Fund; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research & Development ServiceUS Department of Veterans Affairs [I01BX004158]; Research Centers in Minority Institutions (RCMI) - National Institutes of Health [2U54MD007595]; Carol Lavin Bernick Faculty Grant
第一作者机构：[1]Tulane Univ, Dept Struct & Cellular Biol, New Orleans, LA 70112 USA;[3]Kunming Med Univ, Affiliated Hosp 1, Dept Gynecol, Kunming, Yunnan, Peoples R China;
通讯作者：
通讯机构：[12]Southeast Louisiana Vet Hlth Care Syst, 2400 Canal St, New Orleans, LA 70119 USA;[13]Tulane Univ, Sch Med, Dept Struct & Cellular Biol, 1430 Tulane Ave Mailbox 8649, New Orleans, LA 70112 USA
推荐引用方式(GB/T 7714)：
Duan Zhenling,Miller Haiyan D.,Fu Xiaowei,et al.Th17 cells promote tumor growth in an immunocompetent orthotopic mouse model of prostate cancer[J].AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY.2019,7(4):249-261.
APA：
Duan, Zhenling,Miller, Haiyan D.,Fu, Xiaowei,Ge, Dongxia,Jin, Ben...&You, Zongbing.(2019).Th17 cells promote tumor growth in an immunocompetent orthotopic mouse model of prostate cancer.AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY,7,(4)
MLA：
Duan, Zhenling,et al."Th17 cells promote tumor growth in an immunocompetent orthotopic mouse model of prostate cancer".AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY 7..4(2019):249-261
